Central nervous system metastases in women after multimodality therapy for high risk breast cancer
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Background: Central nervous system (CNS) relapse is increasing in breast cancer. This increase may reflect altered failure patterns from adjuvant therapy, more effective systemic therapy with improved control in non-CNS sites, or a resistant breast cancer subtype.
Methods: To determine the factors associated with clinical CNS relapse, we examined response to neoadjuvant chemotherapy (chemosensitivity), time to relapse and sites of relapse in a cohort of 140 patients without evidence of metastasis at presentation.
Results: At 5 years (interquartile range 3–6 years), 44 (31%) patients developed distant metastases, including 13 with CNS metastases. CNS relapse was early (median 24 months after diagnosis) and associated with relapse in bone and liver, suggesting hematogenous dissemination. Those with CNS relapse were younger at diagnosis (40 versus 49 years) and more likely to have lymphovascular invasion in the primary tumor compared with non-CNS metastases. Response to neoadjuvant chemotherapy was not different (69% versus 73% response rate) between the two groups. Extent of residual disease after chemotherapy was strongly associated with relapse outside the CNS but not CNS relapses. The CNS was an isolated or dominant site of metastasis in 8 of 13. Despite treatment, most patients with CNS involvement died of neurologic causes a median of 6 months later.
Conclusion: Breast cancers that develop CNS metastases differ from those that develop metastases elsewhere. Both tumor behavior and reduced chemotherapy accessibility to the CNS may contribute to increased CNS involvement in breast cancer patients treated with multimodality therapy.
- DiStefano, A, Yong Yap, Y, Hortobagyi, GN, Blumenschein, GR (1979) The natural history of breast cancer patients with brain metastases. Cancer 44: pp. 1913-1918
- Paterson, AH, Agarwal, M, Lees, A, Hanson, J, Szafran, O (1982) Brain metastases in breast cancer patients receiving adjuvant chemotherapy. Cancer 49: pp. 651-654
- Pierga, JY, Asselain, B, Jouve, M, Dieras, V, Carton, M, Laurence, V, Girre, V, Beuzeboc, P, Palangie, T, Dorval, T, Pouillart, P (2001) Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy.. Cancer 91: pp. 1079-1089
- Stewart, JF, King, RJ, Sexton, SA, Millis, RR, Rubens, RD, Hayward, JL (1981) Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer.. Euro J Cancer (Oxford) 17: pp. 449-453
- Ahmann, FR, Jones, SE, Moon, TE (1988) The effect of prior adjuvant chemotherapy on survival in metastatic breast cancer. J Surg Oncol 37: pp. 116-122
- Jones, SE, Moon, TE (1988) The effect of prior adjuvant chemotherapy on survival in metastatic breast cancer.. J Sur Oncol 37: pp. 116-122
- Trudeau ME, Eisenhauer E, Dent S, Pritchard KI, Lofters W, Norris B, Muldal A, Lefendre F, Vandenberg T, Verma S: Central nervous system relapse following chemotherapy with docetaxel for metastatic breast cancer. In: Proceedings of the American Society of Clinical Oncology. 32nd Annual meeting, Philadelphia, PA, May 18–21, 1996, p. 15.
- Crivellari, D, Pagani, O, Veronesi, A, Lombardi, D, Nole, F, Thurlimann, B, Hess, D, Borner, M, Bauer, J, Martinelli, G, Graffeo, R, Sessa, C, Goldhirsch, A (2001) High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 12: pp. 353-356
- Weitzen R, Zach L, Kaufman B, Tichler T, Rath P, Pfeffer R, Baram J, Ben David M, Rizel S, Catane R: High incidence of brain metastasis in patients on trastuzumab for advanced breast cancer. In: Proceedings of the American Society of Clinical Oncology. 38th Annual meeting, Orlando, FL, May 18–21, 2002, abstract #1936.
- Wardley AM, Danson S, Clayton AJ, Clemons M, Burt P, Stewart A, Waine S, Wilkinson P, Welch R, Magee B, Howell A: High incidence of brain metastases in patients treated with trastuzumab for metastatic breast cancer at a large cancer center. In: Proceedings of the American Society of Clinical Oncology. 38th Annual meeting, Orlando, FL, May 18–21, 2002, abstract #241.
- Lower, EE, Blau, R, Bismayer, J, Brennan, L, Broun, R, Danneman, W, Drosick, DR, Hawley, DK (2001) Increased brain metastasis detected in metastatic breast cancer patients.. Br Ca Res Treat 69: pp. 357a
- Chock JY, Domchek S, Burstein HJ, Harris L, Younger J, Kuter I, Rue M, Gelman RS, Winer ER: Central nervous system metastases in women who receive trastuzumab for metastatic breast cancer. In: Proceedings of the American Society of Clinical Oncology. 38th Annual meeting, Orlando, FL, May 18–21, 2002, abstract #218.
- Freilich, RJ, Seidman, AD, DeAngelis, LM (1995) Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel.. Cancer 76: pp. 232-236
- Kosmas, C, Malamos, NA, Tsavaris, NB, Stamataki, M, Stefanou, S, Gregoriou, A, Rokana, S, Vartholomeou, M, Antonopoulos, MJ (2002) Leptomeningeal carcinomatosis after major remission to taxane-based front-line therapy in patients with advanced breast cancer.. J Neuro-Oncol 56: pp. 265-236
- Seidman, AD, Fornier, MN, Esteva, FJ, Tan, L, Kaptain, S, Bach, A, Panageas, KS, Arroyo, C, Valero, V, Currie, V, Gilewski, T (2001) Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.. J Clin Oncol 19: pp. 2587-2595
- Singletary, ES, Allred, C, Ashley, P, Bassett, LW, Berry, D, Bland, KI, Burgen, PI, Clark, G, Edge, SB, Hayes, DF, Hughes, LL, Hutter, RVP, Morrow, M, Page, DL, Recht, A, Theriault, RL, Hor, A, Weaver, DL, Wieand, HS, Greene, FL (2002) Revision of the American Joint Committee on Cancer Staging System for Breast Cancer. J Clin Oncol 20: pp. 3628-3636
- WG, Cance, LA, Carey, BF, Calvo, C, Sartor, L, Sawyer, DT, Moore, J, Rosenman, DW, Ollila, Graham 2nd, M (2002) Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival.. Ann Surg 236: pp. 295-302
- Wolmark, N, Wang, J, Mamounas, E, Bryant, J, Fisher, B (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.. J Natl Ca Inst Monographs 30: pp. 96-102
- Kuerer, HM, Sahin, AA, Hunt, KK, Newman, LA, Breslin, TM, Ames, FC, Ross, MI, Buzdar, AU, Hortobagyi, GN, Singletary, SE (1999) Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.. Ann Surg 230: pp. 72-78
- Boogerd, W, Vos, VW, Hart, AA, Baris, G (1993) Brain metastases in breast cancer; natural history, prognostic factors and outcome.. J Neuro-Oncol 15: pp. 165-174
- Kamby, C, Ejlertsen, B, Andersen, J, Birkler, NE, Rytter, L, Zedeler, K, Rose, C (1988) The pattern of metastases in human breast cancer. Influence of systemic adjuvant therapy and impact on survival. Acta Oncol 27: pp. 715-719
- Tsukada, Y, Fouad, A, Pickren, JW, Lane, WW (1983) Central nervous system metastasis from breast carcinoma: Autopsy study. Cancer 52: pp. 2349-2354
- Zimm, S, Wampler, GL, Stablein, D, Hazra, T, Young, HF (1981) Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 48: pp. 384-394
- Monte, SM, Hutchins, GM, Moore, GW (1988) Influence of age on the metastatic behavior of breast carcinoma. Human Pathology 19: pp. 529-534
- Hagemeister, FB, Buzdar, AU, Luna, MA, Blumenschein, GR (1980) Causes of death in breast cancer: a clinicopathologic study. Cancer 46: pp. 162-167
- Miller, KD, Weathers, T, Haney, LG, Timmerman, R, Dickler, M, Shen, J, Sledge, GW (2001) Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Br Ca Res Treat 69: pp. 214a
- Lesser, GJ, Grossman, SA, Eller, S, Rowinsky, EK (1995) The distribution of systemically administered [3H]-paclitaxel in rats: a quantitative autoradiographic study. Cancer Chemotherapy Pharmacol 37: pp. 173-178
- Pestalozzi, BC, Brignoli, S (2000) Trastuzumab in CSF. J Clinl Oncol 18: pp. 2349-2351
- Bendell, JC, Domchek, SM, Burstein, HJ, Harris, L, Younger, J, Kuter, I, Bunnell, C, Rue, M, Gelman, R, Winer, E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.. Cancer 97: pp. 2972-2977
- Viadana, E, Cotter, R, Pickren, JW, Bross, IDJ (1973) An autopsy study of metastatic sites of breast cancer. Cancer Res 33: pp. 179-181
- Schouten, LJ, Rutten, J, Huveneers, HA, Twijnstra, A (2002) Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma.. Cancer 94: pp. 2698-2705
- Clark, GM, Sledge, GW, Osborne, CK, McGuire, WL (1987) Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients.. J Clin Oncol 5: pp. 55-61
- Maki, DD, Grossman, RI (2000) Patterns of disease spread in metastatic breast carcinoma: influence of estrogen and progesterone receptor status.. Am J Neuroradiol 21: pp. 1064-1066
- Lai RK, Dang C, Thaler H, Malkin MG: The incidence of brain metastases in HER2/neu+ stage IV breast cancer patients. In: Proceedings of the American Society of Clinical Oncology. 37th Annual meeting, San Fransisco, CA, May 12–15, 2001, abstract #2014
- Rosenberg, GA (2002) Matrix metalloproteinases in neuroinflammation.. GLIA 39: pp. 279-291
- Central nervous system metastases in women after multimodality therapy for high risk breast cancer
Breast Cancer Research and Treatment
Volume 88, Issue 3 , pp 273-280
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers
- Additional Links
- brain metastasis
- breast cancer
- central nervous system metastasis
- neoadjuvant chemotherapy
- Industry Sectors
- Author Affiliations
- 1. Division of Hematology/Oncology, CB7305, University of North Carolina, 3009 Old Clinic Building, Chapel Hill, NC, 27599-7305, USA
- 2. Division of Neurosurgery, Department of Surgery, Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
- 3. Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
- 4. Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA